Avilar Therapeutics rakes in $60m seed

Avilar Therapeutics, a biopharmaceutical company focused on extracellular protein degradation, has raised $60 million in seed financing.

18 November 2021•1 min read
Feature image
LinkedInXEmail
LinkedInXEmail

Related articles